Latest information on COVID-19

Division of Oncology

in the Department of Medicine

Welcome to the Division of Oncology, a center of excellence in patient care, medical education, and state-of-the-art research. Cancer is a major public health problem and it is also an exciting challenge for discovery and innovation. 

Message from the Chief

A welcome message from the the Division of Oncology's Chief, Dr. Heather Wakelee.

Open Positions

The Division of Oncology is seeking qualified faculty for several open positions.  Successful applicants must hold an MD or MD/PhD degree and be board-certified or board-eligible in Medical Oncology, and have a history of significant peer-reviewed funding. 

Our Mission

  • To engage in research to create the future of cancer care
  • To provide the best in care for cancer patients
  • To train physicians for careers in academic medicine and research



We welcome Drs. Christopher Chen, Nathaniel Myall, and Ali Khaki to the Stanford Oncology faculty!

Dr. Christopher Chen completed his fellowship in medical oncology at Massachusetts General Hospital/Dana-Farber Cancer Institute, and he came to Stanford in August 2020 to join the Gastrointestinal (GI) Oncology team.   Dr. Chen specializes in treating GI malignancies, particularly colorectal cancer.  In addition, he has been appointed Clinical Director of the Early Drug Development Program for the Stanford Cancer Institute.

Dr. Nathaniel Myall completed all of his education and training at Stanford University, and he joined the Stanford faculty in September 2020.  Dr. Myall is one of three physicians comprising the new Med11 Onco-hospitalist team.  He will focus his outpatient clinics and his research efforts in thoracic malignancies and neuroendocrine tumors.   

Dr. Ali Khaki has trained as a hospitalist and oncologist, recently completing his fellowship at University of Washington in Seattle.  He has joined the faculty in January as part of the Med11 team, and his outpatient clinic will focus on genitourinary oncology. Dr. Khaki is also interested in quality of care around end of life and use of real-world data to evaluate novel medications not represented in clinical trials for the treatment of urothelial carcinoma.